Understanding the condition
Dry eye disease is a common, often chronic condition affecting the ocular surface. Its prevalence increases with age.
It results from inadequate tear production, excessive tear evaporation, or a combination of both.
Aqueous-deficient dry eye
The lacrimal glands produce insufficient tears to maintain adequate ocular surface lubrication.
Potential contributing factors include ageing, medications and autoimmune conditions such as Sjögren's disease.
Evaporative dry eye
Tears evaporate excessively, commonly due to meibomian gland dysfunction. These glands produce oils that help stabilise the tear film and reduce evaporation.
Both mechanisms may occur together.
Clinical pearl: Excessive watering does not exclude dry eye disease. An unstable tear film can trigger reflex tear production.
Signs and symptoms
Common symptoms include:
- Gritty, sandy or foreign-body sensation
- Burning, irritation or stinging
- Itching or discomfort
- Intermittent blurred vision
- Eye fatigue
- Excessive watering
- Mild ocular soreness
Symptoms may worsen with prolonged screen use, reduced blinking, air conditioning, wind and low-humidity environments.
Significant eye pain, persistent unilateral redness, photophobia or reduced vision should prompt consideration of an alternative, potentially serious diagnosis.
Common causes and risk factors
Environmental and behavioural
- Prolonged screen use
- Air conditioning, heating and wind
- Reduced blinking
- Contact lens use
Medical conditions
- Meibomian gland dysfunction
- Blepharitis
- Sjögren's disease
- Rheumatoid arthritis
- Rosacea
- Other autoimmune conditions
Medication-related causes
Medicines that may contribute to dry eyes include:
- Anticholinergic medicines
- Antihistamines
- Certain antidepressants
- Oestrogens
- Isotretinoin
- Some antihypertensive medicines
Consider whether symptoms began or worsened after a medication was initiated or its dose changed.
Pharmacy learning point: Identifying a contributing medicine may be more important than recommending another lubricant.
Patient assessment in community pharmacy
Essential assessment questions
- How long have the symptoms been present?
- Are one or both eyes affected?
- Is there pain, redness, photophobia or reduced vision?
- Do you wear contact lenses?
- Is there itching, discharge or crusting?
- Do symptoms worsen during screen use or in air-conditioned environments?
- Have you previously used lubricating drops, gels or ointments?
- How often are you using eye drops?
- Are you taking any medicines that could contribute to dryness?
- Do you experience dry mouth, joint pain or other systemic symptoms?
Differential diagnoses
Consider allergic conjunctivitis, infectious conjunctivitis, blepharitis, corneal injury, keratitis and other ocular surface conditions.
The pharmacist's role is to recognise uncomplicated presentations, provide suitable initial management and identify patients requiring further assessment.
Treatment options in Australian pharmacies
5.1 Ocular lubricants — first-line treatment
Ocular lubricants, commonly called artificial tears, are generally the first-line pharmacological treatment for uncomplicated dry eye disease.
Evidence-based principle from AMH
There is no convincing evidence that one ocular lubricant is universally superior to another.
Selection is usually based on:
- Individual symptom relief
- Patient preference
- Tolerability
- Frequency of administration
- Presence or absence of preservatives
- Formulation characteristics
- Cost and availability
Important: Product properties can guide selection, but theoretical formulation benefits should not be confused with proven clinical superiority.
5.2 Eye drops
Eye drops provide lubrication and temporary relief.
Administration frequency depends on disease severity and product instructions. Some patients may require very frequent administration, potentially as often as hourly.
Examples of Australian pharmacy products
Brand | Main ingredient | Considerations |
|---|---|---|
Refresh Plus | Carmellose sodium 0.5% | Lubricant supplied in single-use vials |
Systane Ultra Preservative-Free | Polyethylene glycol 400 and propylene glycol | Preservative-free lubrication |
HYLO-FRESH | Sodium hyaluronate 0.1% | Preservative-free lubricant |
HYLO-FORTE | Sodium hyaluronate 0.2% | Higher-concentration hyaluronate formulation |
NovaTears | Perfluorohexyloctane | Water-free formulation used for evaporative dry eye |
These are examples rather than an exhaustive comparison.
5.3 Preserved versus preservative-free drops
Some ophthalmic preparations contain preservatives to limit microbial contamination.
However, reduced tear production may decrease the dilution and clearance of preservatives from the ocular surface.
This increases the risk of preservative-related irritation or toxicity, particularly in patients with more severe dry eye disease.
Preservative-free products are preferred when:
- Ocular lubricants are required more than four times daily
- The patient also uses other eye drops
- Ocular surface disease is more severe or preservative intolerance is suspected
Clinical pearl: For a patient requiring frequent lubricant administration, choosing a preservative-free product may be more important than choosing between different lubricant ingredients.
5.4 Eye gels
Eye gels generally remain on the ocular surface longer than conventional drops and may provide more prolonged symptom relief.
Advantages:
- Potentially longer-lasting lubrication
- May reduce the frequency of administration
- Useful when conventional drops provide insufficient duration of relief
Disadvantages:
- May temporarily blur vision
- May feel thicker or less comfortable
- Not necessarily preferred by every patient
Gels generally cause less visual blurring than ointments.
Practical counselling: Explain that temporary blurred vision can occur and that patients should avoid driving until their vision is clear.
5.5 Eye ointments
Ophthalmic lubricating ointments provide prolonged lubrication and are particularly useful for symptoms occurring overnight or on awakening.
They may also be used during the day for severe symptoms when appropriate.
Advantages
- Prolonged ocular surface contact
- Useful for nocturnal symptoms
- Ointment formulations do not contain preservatives
Disadvantages
- Can cause substantial temporary blurred vision
- May be cosmetically inconvenient
- Lanolin in some products can cause irritation
Counselling: Ointments are often best used before bedtime because of their effect on vision.
5.6 Liposomal eye sprays
Liposomal sprays contain phospholipids, often derived from soy lecithin.
They are intended to help stabilise the lipid component of the tear film and reduce tear evaporation.
Administration
- Keep the eyes closed.
- Hold the spray approximately 10 cm from the eyelids.
- Spray onto the closed eyelids according to the product instructions.
- Keep the eyes closed briefly after application.
Liposomal sprays may be considered as an option for patients with symptoms associated with tear evaporation.
Their proposed mechanism does not establish superiority over conventional ocular lubricants.
5.7 Choosing the appropriate formulation
Patient presentation | Considerations |
|---|---|
Mild, occasional dryness | Trial a lubricating eye drop |
Frequent daily drop use | Prefer preservative-free lubrication |
Lubricating drops provide short-lived relief | Consider a gel or alternative formulation |
Symptoms overnight or on awakening | Consider a lubricating ointment |
Suspected evaporative dry eye | Consider lipid-targeting options and assessment of eyelid function |
Persistent symptoms despite treatment | Refer for assessment rather than repeatedly switching products |
Important contact lens considerations
Check the manufacturer's compatibility instructions for each product.
For example, HYLO-FORTE is compatible with contact lenses however waiting at least 30 minutes after instilling HYLO-FORTE before inserting contact lenses is reccomended, whereas NovaTears should not be administered while contact lenses are being worn.
A painful, red eye in a contact lens wearer requires urgent assessment rather than routine lubricant treatment.
5.8 Non-pharmacological management
- Encourage regular blinking and screen breaks.
- Reduce exposure to direct fans and air conditioning.
- Consider environmental humidification.
- Discuss appropriate warm compresses and eyelid hygiene for meibomian gland dysfunction.
- Review contact lens habits where relevant.
- Address potentially contributing medical conditions or medicines.
When to refer
Urgent same-day assessment
Arrange urgent medical or eye-care assessment for:
- Significant or worsening eye pain
- Marked unilateral redness
- Photophobia
- New visual impairment
- Suspected corneal injury or infection
- A painful, red eye in a contact lens wearer
Sudden major vision loss, chemical eye injuries or other severe ocular emergencies require emergency management.
Referral after initial treatment
Consider referral to an optometrist or ophthalmologist when there is an inadequate response after 2–4 weeks of appropriate lubricant treatment.
Referral may be appropriate earlier for persistent or worsening symptoms, suspected underlying systemic disease, significant eyelid pathology or diagnostic uncertainty.
Pharmacy learning point: The 2–4-week recommendation is not a waiting period for patients with red flags. Those patients need assessment immediately or urgently according to the presentation.
References and clinical review
Primary reference
Australian Medicines Handbook (AMH). Dry eye syndrome. Section: Drugs for dry eyes. User-supplied AMH material incorporated into this article.
https://amhonline.amh.net.au/chapters/eye-drugs/drugs-dry-eyes/dry-eye-syndrome
Additional references
Australian Prescriber. Dry eye disease: when to treat and when to refer.
https://australianprescriber.tg.org.au/articles/dry-eye-disease-when-to-treat-and-when-to-refer.html
Healthdirect Australia. Eye care resources.
https://www.healthdirect.gov.au/
Individual Australian manufacturer product information should also be consulted for current formulations, contact lens compatibility, preservatives and administration instructions.
Clinical status: Reviewed by Guy Tov-Ben on 16 November 2026.
Content updated: 14 November 2026
Reviewed by Guy Tov-Ben: 16 November 2026
Next review due: To be scheduled
